NDC 70518-2601-2 - Citalopram

This NDC is not currently matched to an FDA NDC product listing in FDA.report, but it is a valid NDC-form code. FDA.report is showing the available DailyMed label context for the product root.

Product NDC
70518-2601
Requested NDC
70518-2601-2
Package NDCs from labels
70518-2601-0, 70518-2601-2, 70518-2601-1, 70518-2601-3
Manufacturer
REMEDYREPACK INC.
Effective date
2026-07-27
Current FDA listing
Not matched in FDA.report NDC product tables

DailyMed Labels#

Label, Manufacturer, Effective date table
LabelManufacturerEffective dateType
Citalopram - REMEDYREPACK INC.REMEDYREPACK INC.2026-07-27HUMAN PRESCRIPTION DRUG LABEL

FDA-Initiated Inactive NDC Indexing#

NDC, Effective, Related label table
NDCEffectiveRelated label
70518-2601-02022-01-31These highlights do not include all the information needed to use CITALOPRAM TABLETS safely and effectively. See full prescribing information for CITALOPRAM TABLETS . CITALOPRAM tablets, for oral use Initial U.S. Approval: 1998
70518-2601-02022-01-31These highlights do not include all the information needed to use CITALOPRAM TABLETS safely and effectively. See full prescribing information for CITALOPRAM TABLETS . CITALOPRAM tablets, for oral use Initial U.S. Approval: 1998
70518-2601-02022-01-31These highlights do not include all the information needed to use CITALOPRAM TABLETS safely and effectively. See full prescribing information for CITALOPRAM TABLETS . CITALOPRAM tablets, for oral use Initial U.S. Approval: 1998
70518-2601-12022-01-31These highlights do not include all the information needed to use CITALOPRAM TABLETS safely and effectively. See full prescribing information for CITALOPRAM TABLETS . CITALOPRAM tablets, for oral use Initial U.S. Approval: 1998
70518-2601-12022-01-31These highlights do not include all the information needed to use CITALOPRAM TABLETS safely and effectively. See full prescribing information for CITALOPRAM TABLETS . CITALOPRAM tablets, for oral use Initial U.S. Approval: 1998
70518-2601-12022-01-31These highlights do not include all the information needed to use CITALOPRAM TABLETS safely and effectively. See full prescribing information for CITALOPRAM TABLETS . CITALOPRAM tablets, for oral use Initial U.S. Approval: 1998
70518-2601-02022-01-28These highlights do not include all the information needed to use CITALOPRAM TABLETS safely and effectively. See full prescribing information for CITALOPRAM TABLETS . CITALOPRAM tablets, for oral use Initial U.S. Approval: 1998
70518-2601-02022-01-28These highlights do not include all the information needed to use CITALOPRAM TABLETS safely and effectively. See full prescribing information for CITALOPRAM TABLETS . CITALOPRAM tablets, for oral use Initial U.S. Approval: 1998
70518-2601-02022-01-28These highlights do not include all the information needed to use CITALOPRAM TABLETS safely and effectively. See full prescribing information for CITALOPRAM TABLETS . CITALOPRAM tablets, for oral use Initial U.S. Approval: 1998
70518-2601-12022-01-28These highlights do not include all the information needed to use CITALOPRAM TABLETS safely and effectively. See full prescribing information for CITALOPRAM TABLETS . CITALOPRAM tablets, for oral use Initial U.S. Approval: 1998
70518-2601-12022-01-28These highlights do not include all the information needed to use CITALOPRAM TABLETS safely and effectively. See full prescribing information for CITALOPRAM TABLETS . CITALOPRAM tablets, for oral use Initial U.S. Approval: 1998
70518-2601-12022-01-28These highlights do not include all the information needed to use CITALOPRAM TABLETS safely and effectively. See full prescribing information for CITALOPRAM TABLETS . CITALOPRAM tablets, for oral use Initial U.S. Approval: 1998

DailyMed Package Descriptions#

Package NDC, Product, Description table
Package NDCProductDescriptionFormQuantityStrengthSPL version
70518-2601-0Citalopram90 in 1 BOTTLE, PLASTICTABLET, FILM COATED9014
70518-2601-1Citalopram100 in 1 BOXTABLET, FILM COATED10014
70518-2601-2Citalopram1 in 1 POUCHTABLET, FILM COATED114
70518-2601-3Citalopram30 in 1 BLISTER PACKTABLET, FILM COATED3014

DailyMed Dashboard NDC Coverage#

NDC, Dashboard title, SPL version table
NDCDashboard titleSPL versionValidationDashboard ZIP
70518-2601CITALOPRAM TABLET, FILM COATED [REMEDYREPACK INC.]11Current NDC, Legacy NDC, 4 package rows20250322_aa9c1440-354f-43a6-9e70-fd7bafcb03c5.zip

openFDA label cross-check#

OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.

Matched openFDA labels page 1 of 137 · 2,727 matching rows.

Brand, Generic, Manufacturer table
BrandGenericManufacturerSPL set IDEffective dateAvailable safety fieldsJoin
CitalopramCITALOPRAMPD-Rx Pharmaceuticals, Inc.75f6db65-e4ed-470a-9e56-12791f22ee9b2026-11-05Boxed warning, Warnings, Adverse reactionsExact identifier
rxcui: 200371
unii: I1E9D14F36
COOLA 70 PERCENT PLUS ORGANIC MINERAL BODY SUNSCREEN SPF50TITANIUM DIOXIDE, ZINC OXIDECOOLA, LLCcb95c712-1680-4040-e053-2995a90af0042026-11-04WarningsExact identifier
unii: 15FIX9V2JP
Vertra Ehukai Beige Sunscreen Face Stick Broad Spectrum SPF 38TITANIUM DIOXIDEEai-jr 286, Inc303d5d5a-4c7a-1e23-e063-6294a90a0e582026-11-04WarningsExact identifier
unii: 15FIX9V2JP
Vertra Mick Fanning Signature Foundation Sunscreen Face Stick SPF 35 Coolangatta BeigeTITANIUM DIOXIDEEAI-JR 286, Inc.b9ea12e8-6ed9-d805-e053-2a95a90aa1072026-11-04WarningsExact identifier
unii: 15FIX9V2JP
Vertra Pearl White Face Stick SPF 50PADIMATE O, TITANIUM DIOXIDEEai-jr 286, Incb69a75e0-8724-35ae-e053-2a95a90a5f342026-11-04WarningsExact identifier
unii: 15FIX9V2JP
Vertra S Dorian Kona Gold Signature Face Stick SPF 38TITANIUM DIOXIDEEai-jr 286, Incb6c316c3-661b-6428-e053-2a95a90a1a6b2026-11-04WarningsExact identifier
unii: 15FIX9V2JP
HERA SILKYSTAY FOUNDATION 34W1TITANIUM DIOXIDEAmorepacific Corporation5f3ef340-c68e-1790-e063-6394a90a44aa2026-11-01WarningsExact identifier
unii: 15FIX9V2JP
HERA SILKYSTAY FOUNDATION 35C1TITANIUM DIOXIDEAmorepacific Corporation5f40c97f-b90e-bec7-e063-6394a90ae5db2026-11-01WarningsExact identifier
unii: 15FIX9V2JP
HERA SILKYSTAY FOUNDATION 35N1TITANIUM DIOXIDEAmorepacific Corporation5f40f46b-c6b2-df1f-e063-6394a90afd962026-11-01WarningsExact identifier
unii: 15FIX9V2JP
HERA SILKYSTAY FOUNDATION 37W1TITANIUM DIOXIDEAmorepacific Corporation5f4105f3-d08b-edb5-e063-6394a90ad28b2026-11-01WarningsExact identifier
unii: 15FIX9V2JP
HERA SILKYSTAY FOUNDATION 39N1TITANIUM DIOXIDEAmorepacific Corporation5f41120a-521a-f5ac-e063-6394a90ac0212026-11-01WarningsExact identifier
unii: 15FIX9V2JP
HERA SILKYSTAY FOUNDATION 41W1TITANIUM DIOXIDEAmorepacific Corporation5f4158f0-c743-29c2-e063-6394a90ac7212026-11-01WarningsExact identifier
unii: 15FIX9V2JP
HERA SILKYSTAY FOUNDATION 43N1TITANIUM DIOXIDEAmorepacific Corporation5f41ecb2-9fe5-ade7-e063-6294a90abc4e2026-11-01WarningsExact identifier
unii: 15FIX9V2JP
HERA SILKYSTAY FOUNDATION 43O1TITANIUM DIOXIDEAmorepacific Corporation5f425415-ed84-fc33-e063-6394a90a15f72026-11-01WarningsExact identifier
unii: 15FIX9V2JP
HERA SILKYSTAY FOUNDATION 44C1TITANIUM DIOXIDEAmorepacific Corporation5f42d960-6b86-b4cd-e063-6294a90a98f32026-11-01WarningsExact identifier
unii: 15FIX9V2JP
HERA SILKYSTAY FOUNDATION 45N1TITANIUM DIOXIDEAmorepacific Corporation5f4326fc-b3c3-1a8b-e063-6294a90a8d9b2026-11-01WarningsExact identifier
unii: 15FIX9V2JP
HERA SILKYSTAY FOUNDATION 45W1TITANIUM DIOXIDEAmorepacific Corporation5f4335c8-596f-3269-e063-6294a90a6c3d2026-11-01WarningsExact identifier
unii: 15FIX9V2JP
HERA SILKYSTAY FOUNDATION 46W1TITANIUM DIOXIDEAmorepacific Corporation5f43404e-bdab-3f4b-e063-6294a90ab8812026-11-01WarningsExact identifier
unii: 15FIX9V2JP
HERA SILKYSTAY FOUNDATION 47N1TITANIUM DIOXIDEAmorepacific Corporation5f435148-dcb1-cfdf-e063-6394a90aa8b62026-11-01WarningsExact identifier
unii: 15FIX9V2JP
HERA SILKYSTAY FOUNDATION 50N1TITANIUM DIOXIDEAmorepacific Corporation5f43610f-6c4f-dd9d-e063-6394a90ab60a2026-11-01WarningsExact identifier
unii: 15FIX9V2JP

Reported adverse events (FAERS/openFDA)#

Adverse event summaries are temporarily unavailable. Other product information remains available.